An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease

Clinical Cancer Research

Volumn 14, Issue 16, 2008, Pages 5255-5259

  Salama, Joseph K ^a   Chmura, Steven J ^a   Mehta, Neil ^b   Yenice, Kamil M ^a   Stadler, Walter M ^a   Vokes, Everett E ^a   Haraf, Danielj ^a   Hellman, Samuel ^a   Weichselbaum, Ralph R ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b SWC Oncology

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; NONSTEROID ANTIINFLAMMATORY AGENT;

ADRENAL METASTASIS; ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; BONE METASTASIS; BRAIN METASTASIS; CANCER GROWTH; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RESEARCH; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DESQUAMATION; FATIGUE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; LIFE EXPECTANCY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; NAUSEA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PNEUMONIA; SCORING SYSTEM; SOFT TISSUE METASTASIS; TREATMENT OUTCOME; TREATMENT RESPONSE; COMPUTER ASSISTED RADIOTHERAPY; DISEASE FREE SURVIVAL; FEMALE; KAPLAN MEIER METHOD; MALE; METASTASIS; MORTALITY; NEOPLASM; PATHOLOGY; RADIATION DOSE FRACTIONATION;

DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; NEOPLASM METASTASIS; NEOPLASMS; RADIOTHERAPY, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL;

EID: 52649088246     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0358     Document Type: Article

References (25)

1. Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007;357:340-8.
2. Aleman BM, Raemaekers JM.Tirelli U, etal. Involved field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003;348:2396-406.
3. MillerTP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkins lymphoma. N Engl J Med 1998:33921 -6.
4. Argiris A, Li Y, Forastiere A. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 2004;101:2222-9.
5. Escudier B, Eisen T, StadlerWM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
6. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
7. Petrylak DPTangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
8. Sandler A, Gray R, Perry MC, et al. Paclitaxel- carboplatin alone or with bevacizumab for non-small- cell lung cancer. N Engl J Med 2006;355:2542-50.
9. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisne for advanced prostate cancer. N Engl J Med 2004:351: 1502-12.
10. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995;13:8-10.
11. Mehta N, Mauer AM, Hellman S, et al. Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol 2004;25:1677-83.
12. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases.The International Registry of Lung Metastases. J Thorac Cardiovasc Surg 1997;113:37-49.
13. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997:15: 938-46.
14. Miller G, Biernacki P, Kemeny NE, et al. Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg 2007:205:231-8.
15. Strong VE, D'Angelica M.Tang L, et al. Laparoscopic adrenalectomy for isolated adrenal metastasis. Ann Surg Oncol 2007;14:3392-400.
16. Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003;124:1946-55.
17. Zimmermann FB, Geinitz H, Schill S, et al. Stereo tactic hypofractionated radiation therapy for stage I non-small cell lung cancer. Lung Cancer 2005;48: 107-14.
18. SchefterTE, Kavanagh BD, Timmerman RD, Car- denes HR, Baron A, Gaspar LE. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 2005;62: 1371-8.
19. Hoyer M, Roed H,Traberg Hansen A, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 2006;45:823-30.
20. Kavanagh BD, SchefterTE, Cardenes HR, et al. Interim analysis of a prospective phase l/ll trial of SBRT for liver metastases. Acta Oncol 2006;45:848-55.
21. Timmerman RD, Story M. Stereotactic body radiation therapy: a treatment in need of basic biological research. Cancer J 2006;12:19-20.
22. Wersall RJ, Blomgren H, Lax I, etal. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol 2005;77:88-95.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53: 457-81.
24. Gupta GP, Nguyen DX, Chiang AC, et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007;446:765-70.
25. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24.